A meta-analysis of ibuprofen versus indomethacin for closure of patent ductus arteriosus.
Ibuprofen (IBU) has previously been shown to be as effective as indomethacin (INDO) in closing the patent ductus arteriosus (PDA) of preterm infants, without severely affecting renal hemodynamics or basal cerebral blood flow. We conducted a meta-analysis of randomized trials to compare the efficacy and safety of IBU and INDO for treatment of PDA. Data from the nine relevant trials ( n =566), showed no significant difference in the efficacy of IBU and INDO in PDA closure ( P =0.70). However, five trials ( n =443) provided serum creatinine concentration data that revealed a significantly lower increase favoring IBU ( P < 0.001), and urine output data that showed a significantly lower decrease favoring IBU ( P < 0.001). In two trials ( n =188) the proportion of infants who required postnatal oxygen therapy at 28 days (defined as chronic lung disease) was significantly higher with IBU (52/94; 55.3%) than with INDO (38/94; 40.4%, P < 0.05). No statistically significant differences were found in mortality, intraventricular hemorrhage, necrotizing enterocolitis, surgical ligation, sepsis, retinopathy of prematurity, periventricular leukomalacia, length of hospital stay, gastrointestinal bleeding, re-opening of PDA, back-up treatment, surfactant therapy, or days on a ventilator.


CONCLUSIONS
ibuprofen and indomethacin have similar efficacy in patent ductus arteriosus closure, but preterm infants treated with ibuprofen experience lower serum creatinine values, higher urine output, and less undesirable decreased organ blood flow and vasoconstrictive adverse effects.
Thomas
Ronald L
RL
Children's Research Center of Michigan, Children's Hospital of Michigan, 3901 Beaubien Blvd, 48201 Detroit, Michigan, USA. Rthomas@med.wayne.edu
Parker
Graham C
GC
Van Overmeire
Bart
B
Aranda
Jacob V
JV
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D003404:Creatinine / Q000097:blood; D004374:Ductus Arteriosus, Patent / Q000188:drug therapy*; D006801:Humans; D007052:Ibuprofen / Q000627:therapeutic use*; D007213:Indomethacin / Q000627:therapeutic use*; D007231:Infant, Newborn; D007234:Infant, Premature; D010102:Oxygen Inhalation Therapy / Q000706:statistics & numerical data; D016032:Randomized Controlled Trials as Topic; D014554:Urination
D000894:Anti-Inflammatory Agents, Non-Steroidal; D003404:Creatinine; D007052:Ibuprofen; D007213:Indomethacin
Ann Surg. 1996 Sep;224(3):350-5; discussion 355-7
8813263
Eur J Pediatr. 2000 May;159(5):364-8
10834523
Pediatr Res. 1991 Jul;30(1):106-11
1891274
N Engl J Med. 2000 Sep 7;343(10):674-81
10974130
Pediatr Int. 2003 Dec;45(6):665-70
14651538
Pediatrics. 2000 Mar;105(3 Pt 1):485-91
10699097
Cochrane Database Syst Rev. 2000;(2):CD000174
10796168
J Pediatr. 1983 Jun;102(6):895-906
6343572
J Pediatr. 2004 Mar;144(3):386-8
15001951
Pediatr Clin North Am. 1986 Jun;33(3):545-60
3520463
Lancet. 1995 Jul 22;346(8969):255
7616831
N Engl J Med. 2001 Jun 28;344(26):1966-72
11430325
Cochrane Database Syst Rev. 2003;(2):CD003481
12804469
Dev Pharmacol Ther. 1990;14(1):1-14
2311475
Pediatrics. 1994 Apr;93(4):543-50
8134206
JAMA. 2003 Mar 5;289(9):1124-9
12622582
JAMA. 1996 Feb 21;275(7):539-44
8606475
Pediatr Res. 2000 Jan;47(1):36-42
10625080
J Pediatr. 1978 Oct;93(4):647-51
702245
J Pediatr. 1999 Dec;135(6):733-8
10586177
J Perinatol. 2002 Oct-Nov;22(7):535-40
12368968
Eur J Pediatr. 2002 Apr;161(4):202-7
12014386
Biol Neonate. 1988;54(5):254-62
3203119
J Pediatr. 1997 Oct;131(4):549-54
9386657
Pediatrics. 1996 Oct;98 (4 Pt 1):714-8
8885951
Pediatrics. 2003 Apr;111(4 Pt 1):e340-6
12671149
Arch Dis Child Fetal Neonatal Ed. 1997 May;76(3):F179-84
9175948